Curaleaf (OTCMKTS:CURLF) Posts Earnings Results, Beats Estimates By $0.02 EPS

Curaleaf (OTCMKTS:CURLF) issued its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02, Zacks reports. Curaleaf had a negative net margin of 2.62% and a negative return on equity of 0.88%.

Curaleaf Stock Up 10.5%

Shares of CURLF stock traded up $0.96 on Tuesday, hitting $10.12. The stock had a trading volume of 441,775 shares, compared to its average volume of 145,527. The business has a 50 day moving average of $9.56 and a 200 day moving average of $8.31. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of -77.85 and a beta of 1.62. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.52 and a quick ratio of 0.73. Curaleaf has a 12-month low of $5.40 and a 12-month high of $15.15.

Analyst Ratings Changes

A number of research firms have issued reports on CURLF. Citigroup reiterated a “buy” rating on shares of Curaleaf in a research note on Thursday, August 6th. UBS Group set a $6.00 price objective on Curaleaf in a research note on Monday, October 5th. Finally, Zacks Research lowered Curaleaf from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $6.00.

About Curaleaf

Curaleaf Holdings, Inc is a cannabis company that cultivates, processes, distributes and sells cannabis products for medical and adult-use markets. Its portfolio includes cannabis flower, pre-rolls, vaporizers, concentrates, edibles, tinctures, capsules, topicals and other wellness products, offered under brands such as Curaleaf, Select and Grassroots.

The company serves customers through a network of retail dispensaries and wholesale channels in regulated U.S. cannabis markets. Its operations include cultivation and manufacturing facilities as well as dispensaries, with products distributed in multiple states where medical or adult-use cannabis is permitted.